A

AlloVir
D

ALVR

0.44380
USD
0.02
(5.22%)
مفتوح الان
حجم التداول
4,591
الربح لكل سهم
0
العائد الربحي
-
P/E
-1
حجم السوق
51,288,631
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AAPL
    AAPL
    -0.400
    (-0.16%)
    254.140 USD
    AMZN
    AMZN
    1.130
    (0.50%)
    226.010 USD
    GOOGL
    GOOGL
    3.310
    (1.73%)
    194.620 USD
    MSFT
    MSFT
    -1.09
    (-0.25%)
    435.76 USD
    NVDA
    NVDA
    4.180
    (3.10%)
    139.270 USD
    S
    SNAP
    -0.255
    (-2.24%)
    11.145 USD
    TSLA
    TSLA
    12.31
    (2.92%)
    432.92 USD
    ZM
    ZM
    -0.310
    (-0.36%)
    85.350 USD
    المزيد
الأخبار
المقالات

العنوان: AlloVir

القطاع: Healthcare
الصناعة: Biotechnology
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.